Medicenna Therapeutics Acquired | Healthcare M&A Deal

Medicenna Therapeutics has completed the closing of its public offering, a healthcare services other business in Toronto, for approximately CDN$4.44 million. Medicenna Therapeutics is a clinical-stage immunotherapy company developing Superkines targeting cancer and autoimmune diseases, supporting its lead programs through the healthcare M&A financing. The company issued 8,880,000 units at CDN$0.50 per unit, with each unit including one common share and one-half warrant exercisable at $0.65 for three years. This other acquisition-style capital raise by a strategic healthcare services other issuer totals under $10M and includes broker compensation warrants under an agency agreement.